IRCT20200318046812N2
招募中
3 期
Safety and efficacy of Hydroxychloroquine + Azithromycin + Naproxen + Prednisolone” and Hydroxychloroquine + Azithromycin + Naproxen” regimens in comparison with Hydroxychloroquine + kaletra” on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study
Bagheiat-allah University of Medical Sciences0 个研究点目标入组 906 人待定
概览
- 阶段
- 3 期
- 干预措施
- 未指定
- 疾病 / 适应症
- COVID-19.
- 发起方
- Bagheiat-allah University of Medical Sciences
- 入组人数
- 906
- 状态
- 招募中
- 最后更新
- 5年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Diagnosis of COVID\-19 based on either ground glass appearance in chest CT scan or positive RTPCR test for COVID\-19
- •Requiring hospitalization
- •Patient's age between 16 and 100 years
- •Signed informed consent form
排除标准
- •Past history of hospitalization or treatment in hospital for COVID\-19 disease
- •Receiving other antiviral medications such as (Hydroxychloroquine, Kaletra, Ribavirin, Oseltamivir)
- •Uncontrolled diabetes
- •Chemotherapy in the past month
- •Taking immunosuppressive drugs
- •Chronic liver or renal failure
- •Taking daily systemic corticosteroids
- •GI bleeding
- •Pregnancy or Lactation
- •Uncontrolled bacterial infection
结局指标
主要结局
未指定
相似试验
尚未招募
3 期
Hydroxychloroquine, Azithromycine and Zinc for the treatment of SARS-Cov2 infection in Senegal. COVID-19RespiratoryPACTR202005622389003Faculty of Medicine University Cheikh Anta Diop of Dakar Senegal.384
已完成
不适用
Efficacy and safety of hydroxychloroquine for systemic/cutaneous lupus erythematosus or Sjogren's syndrome patients with annular erythema on the face and/or trunkSystemic/cutaneous lupus erythematosus Sjogren's syndromeJPRN-UMIN000004477Kanazawa University Graduate School of Medical Science10
进行中（未招募）
不适用
Efficacy of the treatment with hydroxychloroquine in non responders HIV-infected HAART-treated patients - NDHIV infection (immunological nonresponders).MedDRA version: 9.1Level: LLTClassification code 10008922EUCTR2009-012499-28-ITAZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)40
已完成
3 期
study of hydroxychloroquine in comparison with pioglitazone in patients with type II diabetes mellitusCTRI/2009/091/001036Ipca Laboratories Limited267
招募中
2 期
COVID-19 prophylaxis with hydroxychloroquine in Front-line Health and Allied-Health Care Workers: The COVID-SHIELD TrialCOVID-19 infectionInfection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620000501943Walter and Eliza Hall Institute of Medical Research650